This study is looking at how well a drug called Anakinra works when combined with chemotherapy for pancreatic adenocarcinoma (a type of pancreatic cancer). Researchers want to see if adding Anakinra to standard chemotherapy (Nab-paclitaxel, gemcitabine, and cisplatin before surgery, and 5-Fluorouracil, oxaliplatin, and irinotecan after surgery) can help normalize a specific marker in the blood called CA19-9. This marker can indicate how well treatment is working. You can join if you are 18 or older and have been diagnosed with pancreatic adenocarcinoma. The study aims to enroll 24 participants and is currently unclear about its recruitment status.

Study design

This is an open-label, single-arm study, meaning all participants receive the same treatment and everyone knows what treatment is being given. It plans to enroll 24 participants.

What's involved

You would self-administer Anakinra twice a day, daily, starting on the first day of chemotherapy, with a 2-day break before surgery. You would also receive pre- and post-operative chemotherapy.

Compensation

Not stated in the trial record.

Follow-up

The main goal of the study is measured at 24 months, suggesting follow-up for at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.